Expression of c-kit receptor (CD117) and CD34 in leukemic cells.

abstract：:The management of AF represents a major challenge in patients with CLL, especially in elderly patients with multiple comorbidities who are representative of the majority of patients with CLL. This is especially complex in the case of ibrutinib. Many anticoagulants have potential for pharmacological interaction with ib...

journal_title：Leukemia & lymphoma

authors： Chai KL,Rowan G,Seymour JF,Burbury K,Carney D,Tam CS

更新日期：2017-12-01 00:00:00

abstract：:Bryostatin, a macrocyclic lactone and protein kinase C (PKC) modulator, has been shown to have differentiation and anti-tumor activity against several leukemia cell lines in vitro. In this study, we demonstrated Bryostatin-induced differentiation in B-cell chronic lymphocytic leukemia (B-CLL) cells, characterized by a...

journal_title：Leukemia & lymphoma

authors： Thomas A,Pepper C,Hoy T,Bentley P

更新日期：2004-05-01 00:00:00

abstract：:Infant acute leukemia, known to have a poor outcome with conventional therapy, usually has a molecular rearrangement at chromosome band 11q23. The 11q23 translocation partner is typically at 4q21 in infant ALL, but other 11q23 translocation partners occur in infant ALL and AML. The MLL gene at 11q23, and the AF4 gene ...

journal_title：Leukemia & lymphoma

authors： Hilden JM,Frestedt JL,Kersey JH

更新日期：1997-04-01 00:00:00

abstract：:The number of circulating plasma cells (CPC) was determined on mononuclear cell preparations after Giemsa (morphology) and light chain staining (immunocytochemistry). Both methods gave reproducible and identical results when CPC were 1% or more. Using this limit, no CPC were observed in MGUS (0/11) and primary amyloid...

journal_title：Leukemia & lymphoma

authors： Zandecki M,Facon T,Preudhomme C,Canis F,Izydorczyk V,Lovi V,Hammad M,Bauters F,Cosson A

更新日期：1994-08-01 00:00:00

abstract：:The addition of rituximab to chemotherapy in patients with diffuse large B-cell lymphoma (DLBCL) has been shown to improve outcome in first-line therapy. However, in patients with relapsed or refractory disease, the value of adding rituximab to salvage chemotherapy is less clearly defined. This study performed a match...

journal_title：Leukemia & lymphoma

authors： Mey UJ,Olivieri A,Orlopp KS,Rabe C,Strehl JW,Gorschlueter M,Hensel M,Flieger D,Glasmacher AG,Schmidt-Wolf IG

更新日期：2006-12-01 00:00:00

abstract：:Cytogenetic testing is now routinely performed for the prognostic work-up of multiple myeloma (MM). The abnormalities del(17p), t(4;14) and del(13q) have been established as predictors of poor outcome in patients with MM treated with conventional chemotherapy or stem cell transplant; chromosome 1q gains and 1p losses ...

journal_title：Leukemia & lymphoma

authors： Jiang A,Reece D,Chang H

更新日期：2012-02-01 00:00:00

abstract：:Forty patients, with mainly poor risk haematological malignancies, were given the new regimen FLAG, comprising fludarabine, arabinosyl cytosine and G-CSF. Twenty four patients had acute myeloid leukaemia (AML), 8 patients myelodysplastic syndrome (MDS) and a further 8 patients had a variety of other haematological mal...

journal_title：Leukemia & lymphoma

authors： Nokes TJ,Johnson S,Harvey D,Goldstone AH

更新日期：1997-09-01 00:00:00

abstract：:A growing body of evidence indicates that long non-coding RNA (lncRNA) is involved in the development and progression of many diseases. It has been reported that lncRNA LINC00467 is disregulated in multiple tumors, while its role in acute myeloid leukemia (AML) is still unknown. Here, we find that LINC00467 expression...

journal_title：Leukemia & lymphoma

authors： Lu J,Wu X,Wang L,Li T,Sun L

更新日期：2020-10-15 00:00:00

abstract：:Chronic lymphocytic leukemia (CLL) is at present an incurable disease. All of the drugs used in the treatment of CLL induce apoptosis in the cells, and in vitro responses to glucocorticoid or analogs correlate with in vivo sensitivity to these agents. Since CLL lymphocytes accumulate rather than proliferate, the idea ...

journal_title：Leukemia & lymphoma

authors： McConkey DJ,Chandra J

更新日期：1999-05-01 00:00:00

abstract：:The purpose of this phase 2 study was to determine the activity and safety of six cycles of bendamustine and eight rituximab (RB) as first-line treatment of adult patients with advanced stage non-follicular indolent non-Hodgkin lymphomas (INFL). The primary end-point was the complete response rate (CRR) with expected ...

journal_title：Leukemia & lymphoma

authors： Luminari S,Goldaniga M,Cesaretti M,Orsucci L,Tucci A,Pulsoni A,Salvi F,Arcaini L,Carella AM,Tedeschi A,Pinto A,Stelitano C,Baldini L

更新日期：2016-01-01 00:00:00

abstract：:Glutamate is the major excitatory neurotransmitter of the nervous system. We previously found that glutamate activates normal human T-cells, inducing their adhesion and chemotaxis, via its glutamate receptors of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) subtype 3 (GluR3) expressed in these ce...

journal_title：Leukemia & lymphoma

authors： Ganor Y,Grinberg I,Reis A,Cooper I,Goldstein RS,Levite M

更新日期：2009-06-01 00:00:00

abstract：:The increased number of CD5+ B-cells in some human autoimmune diseases, the frequent commitment of CD5+ B-cells to the production of natural autoantibodies, and the apparent involvement of these cells in the pathogenesis of the autoimmune hemolytic anemia (AIHA) in certain mouse models suggests a causal relationship b...

journal_title：Leukemia & lymphoma

authors： Efremov DG,Ivanovski M,Burrone OR

更新日期：1998-01-01 00:00:00

abstract：:The prognostic significance of rare BCR-ABL1 transcripts is uncertain in the tyrosine kinase inhibitor (TKI) era. In this retrospective study, 40 (1.7%) patients with rare BCR-ABL1 transcripts were identified from a cohort of 2331 chronic myeloid leukemia (CML) patients; 4 types of rare transcripts were identified, in...

journal_title：Leukemia & lymphoma

authors： Xue M,Wang Q,Huo L,Wen L,Yang X,Wu Q,Pan J,Cen J,Ruan C,Wu D,Chen S

更新日期：2019-12-01 00:00:00

abstract：:In order to determine the efficacy of the antifibrinolytic agent tranexamic acid (TA) in reducing bleeding and platelet transfusions during the treatment of acute myeloid leukemia (AML), we conducted a randomized placebo-controlled double-blind study. Patients with AML undergoing induction or postremission consolidati...

journal_title：Leukemia & lymphoma

authors： Shpilberg O,Blumenthal R,Sofer O,Katz Y,Chetrit A,Ramot B,Eldor A,Ben-Bassat I

更新日期：1995-09-01 00:00:00

abstract：:Infections caused by Aspergillus terreus are rare but have been associated with a poor outcome in immunocompromised patients due to frequent resistance to conventional antifungal therapy. This report describes a case of a woman who developed acute necrotizing ulcerative gingivitis (ANUG) due to A. terreus during induc...

journal_title：Leukemia & lymphoma

authors： Khoury H,Poh CF,Williams M,Lavoie JC,Nevill TJ

更新日期：2003-04-01 00:00:00

abstract：:The ubiquitin-proteasome-dependent proteolytic system has been reported to regulate apoptotic cell death in many experimental cell models. We recently found that B-CLL (chronic lymphocytic leukemia) lymphocytes are hypersensitive to apoptotic death activation through specific inhibition of proteasome function by lacta...

journal_title：Leukemia & lymphoma

authors： Masdehors P,Merle-Béral H,Magdelénat H,Delic J

更新日期：2000-08-01 00:00:00

abstract：:Rapamycin and its derivatives have been proposed in the treatment of leukemia based on their cytostatic effects, but their possible role in differentiation therapy is less explored. The aim of the present study was to investigate the possible beneficial effects of the combination of rapamycin and dimethyl sulfoxide (D...

journal_title：Leukemia & lymphoma

authors： Lalic H,Lukinovic-Skudar V,Banfic H,Visnjic D

更新日期：2012-11-01 00:00:00

abstract：:Idiotypic determinants are potential patient-specific tumor antigens in multiple myeloma (MM). In this study, we have determined the DNA sequence of the variable region of the tumor immunoglobulin (Ig) in 6 patients with MM. We then selected high affinity class I-restricted T-cell peptide epitopes in tumor Ig using tw...

journal_title：Leukemia & lymphoma

authors： Szea DM,Brown RD,Yang S,Gibson J,Ho J,Fazekas de St Groth B,Basten A,Joshua DE

更新日期：2003-09-01 00:00:00

abstract：:Thalidomide represents a recent and innovative therapeutic approach in multiple myeloma. Main toxicity usually consists in somnolence, constipation, peripheral neuropathy and deep vein thrombosis, but, unlike alkylating agents, thalidomide is reported to rarely induce severe hematologic toxicity. The majority of patie...

journal_title：Leukemia & lymphoma

authors： Mazzotta S,Gozzetti A,Pirrotta MT,Bocchia M,Sammassimo S,Bucalossi A,Lauria F

更新日期：2005-12-01 00:00:00

abstract：:The mammalian target of rapamycin (mTOR) pathway is a major therapeutic target in the treatment of hematological malignancies, as it controls cellular events of high importance for regulation of mRNA translation and protein production. Rapalogs, or first-generation mTOR inhibitors, have produced only modest clinical b...

journal_title：Leukemia & lymphoma

authors： Mohindra NA,Platanias LC

更新日期：2015-01-01 00:00:00

abstract：:Myelofibrosis with myeloid metaplasia (MMM) is a clonal stem cell disorder that is characterized by florid bone marrow stromal reaction including collagen fibrosis, osteosclerosis, and angiogenesis. Almost all patients with MMM display increased bone marrow microvessel density (MVD) and the extent is among the highest...

journal_title：Leukemia & lymphoma

authors： Arora B,Mesa R,Tefferi A

更新日期：2004-12-01 00:00:00

abstract：:CD30 ligand (CD30L) is a type-II membrane glycoprotein capable of transducing signals through its specific counterstructure CD30. Even though there are indications that CD30L plays a key role as a paracrine-acting surface molecule in the deregulated cytokine cascade of Hodgkin's disease, little is known about its biol...

journal_title：Leukemia & lymphoma

authors： Gattei V,Degan M,Rossi FM,de Iuliis A,Mazzocco FT,Serraino D,Zagonel V,Aldinucci D,Pinto A

更新日期：1999-09-01 00:00:00

abstract：:Mastocytosis comprises a heterogeneous group of disorders characterized by proliferation and accumulation of mast cells in 1 or more organ systems. Mast cell leukemia (MCL) is an extremely rare subtype of mastocytosis in which a leukemic spread of mast cells and a rapid progression of disease is seen. In typical cases...

journal_title：Leukemia & lymphoma

authors： Noack F,Sotlar K,Notter M,Thiel E,Valent P,Horny HP

更新日期：2004-11-01 00:00:00

abstract：:Infectious complications following treatment of acute myeloid leukemia (AML) are important causes of morbidity and mortality. The spectrum and complexity of these infections is reflected by the severe net state of immunosuppression of AML patients, that is dynamic and continuously changing, the polypharmacy, including...

journal_title：Leukemia & lymphoma

authors： Mulanovich V,Kontoyiannis DP

更新日期：2018-06-01 00:00:00

abstract：:Lymphoid recovery following myeloablative stem cell transplantation (SCT) displays a logistic pattern of exponential growth followed by a plateau. Within this logistic framework, lymphoid recovery is characterized by the parameters R (slope of ascent), a (time of maximal rate of ascent) and K (plateau), the 'steady-st...

journal_title：Leukemia & lymphoma

authors： Kobulnicky DJ,Sabo RT,Sharma S,Shubar Ali AS,Kobulnicky KM,Roberts CH,Clark WB,Chung HM,McCarty JM,Toor AA

更新日期：2018-12-01 00:00:00

abstract：:Classical Hodgkin's disease (HD) is a peculiar form of lymphoma characterized by a low frequency of tumor cells, the so-called Hodgkin (H) and Reed/Sternberg (RS) cells, embedded in a background of non-neoplastic (reactive) cells believed to be recruited and activated by H-RS cell-derived cytokines/chemokines. How the...

journal_title：Leukemia & lymphoma

authors： Aldinucci D,Olivo K,Lorenzon D,Poletto D,Gloghini A,Carbone A,Pinto A

更新日期：2005-03-01 00:00:00

abstract：:Multiple myeloma represents a B cell malignancy characterized by a monoclonal proliferation of plasma cells. A striking feature of the disease is the tendency of the malignant plasma cells to affect mainly the bone marrow environment and to invade the peripheral blood only in the terminal stage. The growth of myeloma ...

journal_title：Leukemia & lymphoma

authors： Van Riet I,Van Camp B

更新日期：1993-04-01 00:00:00

abstract：:According to the International Workshop on Chronic Lymphocytic Leukemia/National Institutes of Health (iwCLL/NIH) guidelines for the diagnosis and treatment of chronic lymphocytic leukemia (CLL), bone marrow biopsy (BMB) is not required at diagnosis, however recommended before initiating treatment. That notwithstandin...

journal_title：Leukemia & lymphoma

authors： Baliakas P,Kanellis G,Stavroyianni N,Fameli M,Anagnostopoulos A,Stamatopoulos K,Papadaki T

更新日期：2013-11-01 00:00:00

abstract：:Infection with the Epstein-Barr virus (EBV) is common worldwide. A significant number of infected individuals develop infectious mononucleosis (IM). IM is manifested in most patients as a benign disease with mild symptoms. However, serious complications may develop in a subset of patients. Because EBV-infected B lymph...

journal_title：Leukemia & lymphoma

authors： Wright-Browne V,Schnee AM,Jenkins MA,Thall PF,Aggarwal BB,Talpaz M,Estrov Z

更新日期：1998-08-01 00:00:00

abstract：:We investigated the role of the leptin receptor (Ob-R) and its relationship with PI3K/AKT activation in diffuse large B-cell lymphoma (DLBCL) clinical samples followed by in vitro studies using a panel of CRC cell lines. Leptin exerts its physiological action through its receptor Ob-R. Overexpression of Ob-R has been ...

journal_title：Leukemia & lymphoma

authors： Uddin S,Bu R,Ahmed M,Hussain AR,Ajarim D,Al-Dayel F,Bavi P,Al-kuraya KS

更新日期：2010-07-01 00:00:00